CClinicalTrials.gg
Not yet recruitingNCT05794633Updated Sep 14, 2023

Acupuncture Therapy in Patients With Subacromial Impingement Syndrome

An interventional study of Acupuncture and Placebo acupuncture in Acupuncture and Subacromial Impingement Syndrome, sponsored by Fatih Sultan Mehmet Training and Research Hospital. Not yet recruiting. Open to participants aged 20 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-09-14.

Sponsored by Fatih Sultan Mehmet Training and Research Hospital · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Nov 2023, 2 years 10 months ago, but the record still lists the study as not yet recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
20 Years to 65 Years
Sex
All
01

Study summary

Shoulder pain is highly prevalent within general population, and shoulder impingement syndrome (SIS) is a common cause of shoulder pain. A small number of clinical and methodologically diverse trials have been published recently which show little evidence to support or refute the use of acupuncture for shoulder pain. Some researchers concluded, there is a need for further well-designed clinical trials. Our aim in this study is to investigate the effect of acupuncture treatment on pain, range of motion, functionality and quality of life in patients diagnosed with Subacromial Impingement Syndrome as a result of clinical and radiological tests.

Read the detailed description

A randomized, prospective, double-blinded, placebo-controlled trial will be conducted. Patients diagnosed with shoulder impingement syndrome will be divided into two groups (acupuncture and placebo acupuncture) The evaluation will be performed at treatment initiation and at the end of the treatment and 1 month after treatment initiation.All patients will be evaluated by the same physiatrist who are blinded to the randomization process and treatment protocols.Primary outcome is pain which will be evaulated with visual analogue scale (VAS) for rest, activity, and sleep-disturbing. Secondary outcomes are shoulder range of motion in all groups will be evaluated with goniometer, shoulder function which will be evaulated with the Shoulder Pain and Disability Index (SPADI) and The Disabilities of the Arm, Shoulder and Hand Score (QuickDash) and quality of life in all groups will be evaluated with The Western Ontario Rotator Cuff Index (WORC).

02

Conditions studied

  • Acupuncture
  • Subacromial Impingement Syndrome
03

In context

Shoulder Impingement Syndrome

304 studies on the registry are indexed under Shoulder Impingement Syndrome; 55 are open to participants now.

This study's planned enrollment of 80 is above the median of 54 across 261 interventional studies indexed under Shoulder Impingement Syndrome.

Browse Shoulder Impingement Syndrome studies →

Lead sponsor

Fatih Sultan Mehmet Training and Research Hospital is the lead sponsor of 118 studies on the registry; 34 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Clinical diagnosis of Subacromial impingement syndrome
  • Age range from 20-65 years
  • Pain VAS ≥ 4
  • Shoulder impingement symptoms lasting at least 6 weeks

Exclusion criteria

Exclusion Criteria:

  • Presence of other shoulder pathologies
  • Previous applications of physiotherapy and injection of hyaluronic acid and/or corticosteroid during the preceding 3 months;
  • Presence of cervical pain or other conditions such as fibromyalgia confusing the clinical picture
  • Presence of malignancy, blood disorder, neurologic, motor, and/or sensory deficit in the upper extremity;
  • Pregnancy,
  • Local anesthetic allergy
  • Previous acupuncture treatment
  • History of deformities, fractures, or surgery of the shoulder
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Acupuncture Group

    The patients will be recieved two days a week for 8 sessions with sterile 25\*40 mm needles.Selected points are as local points, 2 painful points (ahshi point) in the shoulder region, Large intestine 4, 15, Gallbladder 21, Triple warmer 5, 14 Small intestine 9; as distant points Gallbladder 34 and Stomach 38. Patients will recieve also exercise treatment for 8 weeks and coldpack for 4 weeks

    Other: Acupuncture

  • Placebo comparator
    Placebo Acupuncture Group

    The patients will be recieved two days a week for 8 sessions with placebo needle. Selected points are Large intestine 15 Triple warmer 14 gallbladder 21 and small intestine 9. We will use the Placebo needle (blunt needle, tip obtuse, when acupuncture the feeling is similar to acupuncture needles into the skin, but it retracts instead of piercing the skin) to conduct acupuncture treatment. The retention time will be the same as those in the acupuncture group. The specialist will give the subjects verbal cues before and during the acupuncture manipulation, which further reduces the subjects' doubts about the authenticity of acupuncture in the this group. To ensure the implementation of the blinding method, all patients will be treated independently and avoid contacting with each other. Patients will recieve also exercise treatment for 8 weeks and coldpack for 4 weeks

    Other: Placebo acupuncture

Interventions

  • OtherAcupuncture

    The patients will be recieved two days a week for 8 sessions with sterile 25\*40 mm needles.Selected points are as local points, 2 painful points (ahshi point) in the shoulder region, Large intestine 4, 15, Gallbladder 21, Triple warmer 5, 14 Small intestine 9; as distant points Gallbladder 34 and Stomach 38. Patients will recieve also exercise treatment for 8 weeks and coldpack for 4 weeks

  • OtherPlacebo acupuncture

    The patients will be recieved two days a week for 8 sessions with placebo needle. Selected points are Large intestine 15 Triple warmer 14 gallbladder 21 and small intestine 9. We will use the placebo needle (blunt needle, tip obtuse, when acupuncture the feeling is similar to acupuncture needles into the skin, but it retracts instead of piercing the skin) to conduct acupuncture treatment. The retention time will be the same as those in the acupuncture group. The specialist will give the subjects verbal cues before and during the acupuncture manipulation, which further reduces the subjects' doubts about the authenticity of acupuncture in the this group. To ensure the implementation of the blinding method, all patients will be treated independently and avoid contacting with each other. Patients will recieve also exercise treatment for 8 weeks and coldpack for 4 weeks

06

What researchers measure

Primary outcomes

  1. Pain intensity

    All groups will be evaluated for shoulder pain with visual analogue scale (VAS) for rest, activity, and sleep-disturbing.

    Time frame: 2 months

  2. Shoulder Pain and Disability Index

    All groups will be evaluated for shoulder function with the Shoulder Pain and Disability Index (SPADI). SPADI:The pain dimension consists of five questions regarding the severity of an individual's pain. Functional activities are assessed with eight questions designed to measure the degree of difficulty an individual has with various activities of daily living that require upper-extremity use. To answer the questions, patients place a mark on a 10cm visual analogue scale for each question. Higher results indicate worse function.

    Time frame: 2 months

  3. The Disabilities of the Arm, Shoulder and Hand Score

    All groups will be evaluated for shoulder function with The Disabilities of the Arm, Shoulder and Hand Score (QuickDash). The QuickDASH only contains 11 items. It is a questionnaire that measures an individual's ability to complete tasks, absorb forces, and severity of symptoms. The QuickDASH tool uses a 5-point Likert scale from which the patient can select an appropriate number corresponding to his/her severity/function level. Higher results indicate worse function.

    Time frame: 2 months

Secondary outcomes

  1. Shoulder range of motion

    All groups will be evaluated for shoulder range of motion with goniometer.

    Time frame: 2 months

  2. Quality of life index

    Quality of life: All groups will be evaluated for quality of life with The Western Ontario Rotator Cuff Index (WORC). Each item in WORC has a possible score from 0-100 (100mm VAS). Scores can be computed for individual subscales and summated for a total score, which can range from 0-2100, with a higher score representing lower quality of life.

    Time frame: 2 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 14, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05794633
Lead sponsor
Fatih Sultan Mehmet Training and Research Hospital
Responsible party
Duygu Karamanlıoğlu (Principal investigator, Fatih Sultan Mehmet Training and Research Hospital) — Principal investigator
First posted
Apr 3, 2023
Start date
Sep 12, 2023 (estimated)
Primary completion
Nov 20, 2023 (estimated)
Completion
Jan 20, 2024 (estimated)
Last update
Sep 14, 2023

Study contacts

Duygu Silte Karamanlioglu
Contact
drduygusilte@hotmail.com
00905323074990
Duygu Silte Karamanlioglu
principal investigator · Fatih Sultan Mehmet Traning and Research Hospital
Meryem Yilmaz Kaysin
study chair · Fatih Sultan Mehmet Traning and Research Hospital
Feyza Akan Begoglu
study chair · Fatih Sultan Mehmet Traning and Research Hospital
Pinar Akpinar
study chair · Fatih Sultan Mehmet Traning and Research Hospital
Feyza Unlu Ozkan
study chair · Fatih Sultan Mehmet Traning and Research Hospital
Ilknur Aktas
study chair · Fatih Sultan Mehmet Traning and Research Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion